Managing partner at Thuja Capital Management B.V. (Thuja Capital), with the firm since 2008.

After a career in drug research & development of small molecules and biologics (Janssen/J&J, Yamanouchi, Crucell) Michel joined Thuja Capital in 2008, building it into the firm it is today with EUR 130M under management across 3 funds.

He has been on the board of numerous portfolio companies among which are Nightbalance (sold to Philips), Milabs (sold to Rigaku) and Esobiotec (sold to AstraZeneca).